Commonly asked questions about EYLEA and Diabetic Retinopathy Commonly asked questions about EYLEA and Diabetic Retinopathy Understanding DR

Frequently Asked Questions

Have questions about EYLEA or Diabetic Retinopathy (DR)? We have answers.

Diabetic Retinopathy (DR) happens when too much blood sugar (glucose) damages the blood vessels in the retina. As a result, the retina does not get enough blood and nutrients, and blood vessels can leak blood into the retina.
In the United States between 2005 and 2008, more than 25% of people 40 years and older who had diabetes also had a serious eye condition that could cause vision loss. DR is the leading cause of vision loss in working-age adults.
Yes, DR is a complication of diabetes and occurs when too much blood sugar (glucose) damages the blood vessels in the retina.
Regular eye exams are an important factor in detecting DR. Your doctor may perform tests such as a dilated eye exam to detect certain retinal diseases like DR.
DME is a complication of DR, and occurs if the macula, the area of the retina at the back of the eye responsible for sharp central vision, swells with fluid leaked from damaged blood vessels.
With DR, you may not experience any symptoms during early stages of the disease. But as the disease progresses and sugar in the blood goes uncontrolled, symptoms like blurriness or floating spots in your vision (floaters) may occur.
EYLEA is a prescription medicine approved by the Food and Drug Administration for the treatment of DME and DR, as well as Wet Age-related Macular Degeneration (Wet AMD) and Macular Edema following Retinal Vein Occlusion (MEfRVO). You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Your eye doctor will diagnose you with a retina condition that may be treated with EYLEA. A retina specialist is an ophthalmologist specially trained to diagnose and treat retina conditions such as DR.

Not sure what to ask your doctor? Read our discussion guide.
EYLEA works by blocking vascular endothelial growth factor (VEGF), a protein. At high levels, VEGF can cause abnormal blood vessels to grow in the eye and leak fluid (the part of the retina responsible for sharp central vision).

Blocking VEGF can help reduce the fluid leaking into the macula.
EYLEA may work differently for different people. EYLEA has been studied in more than 3,000 people with certain diseases of the retina. Individual results may vary, but you can learn more about how EYLEA helped treat DR here. Discuss with your eye care team what treatment schedule with EYLEA may be right for you.
Anti-VEGF (Anti-Vascular Endothelial Growth Factor) is a treatment for certain retinal diseases designed to block VEGF (a protein that, at high levels, can cause blood vessels to leak fluid and also result in the growth of abnormal blood vessels).
There is no cure for DR. Treatment with EYLEA, however, has been shown to reduce the severity in many people with DR. In 1 clinical study, at 6 months of treatment, 58% of patients had improvement compared to 6% in the control group; at 1 year of treatment, 80% of people who received EYLEA every 2 months* had reduction in disease severity compared to 15% in the control group. Improvement was defined as at least a 2-step improvement on the DR Severity Scale from baseline.

*Patients received EYLEA every 2 months after 5 initial monthly doses
Anyone who has an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept, should not use EYLEA.

Read more about safety with EYLEA.
The most common side effects reported in people receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.

Read more about safety with EYLEA.

EYLEA must only be administered by a qualified eye doctor. Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA. If your eye becomes red, sensitive to light, painful, or develops a change in vision, seek immediate care from an eye doctor.

In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your eye doctor may monitor this after each injection.

There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.

Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.

You may experience temporary visual problems after receiving EYLEA and also during and/or after the eye doctor visits that will follow. Avoid driving or using machinery until your sight has recovered.

Because EYLEA is composed of large molecules, your body may react to it; therefore, there is a potential for an immune response (allergy-like) in patients treated with EYLEA.

Your eye doctor will examine, wash, and numb your eye and then administer EYLEA as an injection into the eye. Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA. Talk to your eye doctor if you experience any side effects, including eye pain, redness of the eye, light sensitivity, or blurring of vision.

Learn more about the treatment experience with EYLEA.
It is important not to miss a scheduled injection of EYLEA. If you do, be sure to make a new appointment as soon as possible.

Learn more about the treatment experience with EYLEA.
Each person responds to treatment with EYLEA differently, including any effects of treatment. Talk with your eye doctor about your individual response and expectations over time—he or she will monitor your progress at every step of your treatment plan.

You can learn how to monitor your vision at home with the Amsler Grid, too.
If you have government insurance (like Medicare) and need help with your EYLEA out-of-pocket costs, Alternate Coverage Referral may be available.

Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided.
Eligible patients with commercial insurance may pay as little as a $0 copay for each EYLEA treatment with the EYLEA Copay Card. Subject to annual assistance limits.

EYLEA also has other programs available—depending on your insurance situation—to help eligible patients with the cost of EYLEA.
EYLEA4U® is a support program that may be able to help. Either you or your eye doctor's office can call 1-855-EYLEA4U (1-855-395-3248), Option 4, Monday through Friday 9 AM to 8 PM Eastern Time to get you started.
When your eye doctor prescribes EYLEA, whether you have private or government insurance (Medicare/Medicaid) or have no insurance coverage, you can be confident that EYLEA4U is here to help. And we can conduct a Benefits Investigation with your insurer to determine your coverage for EYLEA.
IMPORTANT SAFETY INFORMATION
  • EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

For U.S. Residents Only

EYLEA AND EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

© 2019, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road,
Tarrytown, NY 10591

05/2019
US-LEA-14281h US-LEA-14281h

 

Searching with Lea

Close
MENU